For the Inventor, By the Inventor

Enter inventor name

Sandy, UT, United States of America

Steven L Warner

USPTO Granted Patents = 36 (Patent Applications = 25)

EPO Patents = 10 (Patent Applications = 15)

Average Co-Inventor Count = 4.7

ph-index = 11

Forward Citations = 263(Granted Patents)

Location History:

Tucson, AZ (US) (2007 - 2008)
Lehi, UT (US) (2020)
Sandy, UT (US) (2013 - 2023)

Company Filing History:

Tolero Pharmaceuticals, Inc.

10 out of 1,644

University of Utah Research Foundation

University of Arizona

Sumitomo Pharma Oncology, Inc.

Montigen Pharmaceuticals, Inc.

Sumitomo Dainippon Pharma Oncology, Inc.

7. 2 out of 277

Mannkind Corporation

Astex Pharmaceuticals, Inc.

Astex Pharmaceutials, Inc.

where one patent can have more than one assignee

Years Active: 2007-2023

Loading Chart...

Loading Chart...

36 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11746103 - ALK-5 inhibitors and uses thereof (2023-09-05),

2. 11712433 - Compositions comprising PKM2 modulators and methods of treatment using the same (2023-08-01),

3. 11529350 - Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof (2022-12-20),

4. 11497756 - Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib (2022-11-15),

5. 11471456 - Formulations comprising heterocyclic protein kinase inhibitors (2022-10-18),

6. 11400091 - AXL kinase inhibitors and use of the same (2022-08-02),

7. 11040038 - Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same (2021-06-22),

8. 10835537 - Combination therapies for treatment of cancer (2020-11-17),

9. 10752594 - JAK1 and ALK2 inhibitors and methods for their use (2020-08-25),

10. 10682356 - Combination therapies for treatment of cancer (2020-06-16),

11. 10624880 - Predicting response to alvocidib by mitochondrial profiling (2020-04-21),

12. 10568887 - Combination therapies for treatment of cancer (2020-02-25),

13. 10422788 - Profiling peptides and methods for sensitivity profiling (2019-09-24),

14. 10357488 - Predicting response to alvocidib by mitochondrial profiling (2019-07-23),

15. 10267787 - Profiling peptides and methods for sensitivity profiling (2019-04-23),

Title: Spotlight on Inventor Steven L Warner from Sandy, UT

Introduction:

Steven L Warner, a prolific inventor based in Sandy, UT, has made remarkable contributions to the field of pharmaceuticals with a total of 36 patents to his name. His innovative work has focused on the development of novel compounds and treatments for a range of diseases, particularly proliferative diseases like cancer.

Latest Patents:

Warner's latest patents showcase his expertise in pharmacology and drug development. One of his recent patents involves the development of ALK-5 inhibitors for treating and preventing diseases, including cancer. Additionally, he has patented compositions comprising PKM2 modulators for treating PKM2-mediated diseases or disorders.

Career Highlights:

During his career, Steven L Warner has worked with esteemed organizations such as Tolero Pharmaceuticals, Inc. and the University of Utah Research Foundation. His tenure with these institutions has allowed him to further his research and bring innovative solutions to the pharmaceutical industry.

Collaborations:

Collaboration plays a key role in the success of any inventor, and Warner has had the privilege of working alongside accomplished professionals like David J Bearss and Hariprasad Vankayalapati. Through collaboration, Warner has been able to leverage diverse expertise and insights to drive his inventions forward.

Conclusion:

In conclusion, Steven L Warner stands as a pioneering inventor in the field of pharmaceuticals, with a strong track record of patenting novel compounds and treatment methods. His dedication to developing innovative solutions for complex diseases underscores his commitment to advancing healthcare and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…